Quick Answer
IRADIMED CORP reported Total Revenue of $83.81 million for fiscal year 2025.
IRADIMED CORP — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $83.81M +14.4% |
$73.24M +11.7% |
$65.56M +23.0% |
$53.30M +27.5% |
$41.81M +31.8% |
$31.72M -17.7% |
| Net Income | $22.48M +16.9% |
$19.23M +11.9% |
$17.19M +34.0% |
$12.83M +37.6% |
$9.33M +581.2% |
$1.37M -85.8% |
| Diluted EPS | $1.75 +16.7% |
$1.50 +11.1% |
$1.35 +32.4% |
$1.02 +37.8% |
$0.74 +572.7% |
$0.11 -85.9% |
| Total Assets | $108.78M +10.6% |
$98.33M +6.7% |
$92.16M +7.8% |
$85.51M +3.2% |
$82.88M +16.6% |
$71.07M +6.5% |
| Cash and Equivalents | $51.16M -2.1% |
$52.23M +5.0% |
$49.76M -14.1% |
$57.96M -6.5% |
$62.00M +23.8% |
$50.07M +15.1% |
| Stockholders Equity | $94.62M +9.0% |
$86.82M +21.6% |
$71.42M -3.1% |
$73.67M +2.1% |
$72.17M +17.6% |
$61.38M +10.6% |
| R&D Expense | $2.98M +5.0% |
$2.83M -0.9% |
$2.86M +25.5% |
$2.28M +19.6% |
$1.91M +0.1% |
$1.90M +32.8% |
| Operating Income | $26.15M +19.0% |
$21.96M +9.6% |
$20.04M +28.2% |
$15.63M +59.2% |
$9.82M +1398.5% |
-$756.1K -108.7% |
| Gross Profit | $64.32M +14.2% |
$56.35M +12.3% |
$50.16M +21.5% |
$41.28M +28.8% |
$32.05M +36.0% |
$23.57M -20.6% |
| Shares Outstanding | 12.78M +0.6% |
12.71M +0.4% |
12.66M +0.6% |
12.59M +0.4% |
12.54M +1.9% |
12.31M +4.6% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $21.20M | +15.7% | +3.9% |
| Net Income | September 30, 2025 | $5.58M | +10.4% | -3.4% |
| Diluted EPS | September 30, 2025 | $0.43 | +7.5% | -4.4% |
| Total Assets | September 30, 2025 | $114.72M | +21.7% | +7.8% |
| Cash and Equivalents | September 30, 2025 | $56.53M | +9.3% | +6.7% |
| Stockholders Equity | September 30, 2025 | $98.35M | +17.9% | +4.3% |
| R&D Expense | September 30, 2025 | $674.4K | +5.5% | -23.1% |
| Operating Income | September 30, 2025 | $6.83M | +18.0% | +0.7% |
| Gross Profit | September 30, 2025 | $16.49M | +16.2% | +3.4% |
| Shares Outstanding | September 30, 2025 | 12.72M | +0.4% | +0.0% |
- IRADIMED CORP reported Total Revenue of $83.81 million for fiscal year 2025.
- IRADIMED CORP showed an increase of +14.4% in Total Revenue compared to the prior fiscal year.
- IRADIMED CORP reported Net Income of $22.48 million for fiscal year 2025.
- IRADIMED CORP showed an increase of +16.9% in Net Income compared to the prior fiscal year.
- IRADIMED CORP reported Diluted EPS of $1.75 per share for fiscal year 2025.
- IRADIMED CORP showed an increase of +16.7% in Diluted EPS compared to the prior fiscal year.
- IRADIMED CORP reported Total Assets of $108.78 million for fiscal year 2025.
- IRADIMED CORP showed an increase of +10.6% in Total Assets compared to the prior fiscal year.
- IRADIMED CORP reported Cash and Equivalents of $51.16 million for fiscal year 2025.
- IRADIMED CORP showed a decrease of -2.1% in Cash and Equivalents compared to the prior fiscal year.
- IRADIMED CORP reported Stockholders Equity of $94.62 million for fiscal year 2025.
- IRADIMED CORP showed an increase of +9.0% in Stockholders Equity compared to the prior fiscal year.
- IRADIMED CORP reported R&D Expense of $2.98 million for fiscal year 2025.
- IRADIMED CORP showed an increase of +5.0% in R&D Expense compared to the prior fiscal year.
- IRADIMED CORP reported Operating Income of $26.15 million for fiscal year 2025.
- IRADIMED CORP showed an increase of +19.0% in Operating Income compared to the prior fiscal year.
- IRADIMED CORP reported Gross Profit of $64.32 million for fiscal year 2025.
- IRADIMED CORP showed an increase of +14.2% in Gross Profit compared to the prior fiscal year.
- IRADIMED CORP reported Shares Outstanding of 12.78 million shares for fiscal year 2025.
- IRADIMED CORP showed an increase of +0.6% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: